PDS Biotechnology Corporation received a deficiency letter from the Nasdaq Listing Qualifications Department on February 25, 2026. The company's common stock closing bid price has been below the minimum $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). This deficiency has no immediate effect on the listing of the company's common stock, which will continue to trade under the symbol PDSB. PDS Biotechnology has a compliance period of 180 calendar days, until August 24, 2026, to regain compliance. To regain compliance, the company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If compliance is not regained by August 24, 2026, the company may be eligible for a second 180-day compliance period if it meets other listing standards and notifies Nasdaq of its intent to cure. Failure to regain compliance by the end of the applicable period will result in the common stock becoming subject to delisting. The company intends to monitor its common stock's closing bid price and may consider options such as initiating a reverse stock split to regain compliance.